$AMED
AMEDISYS INC

2022 Q4 Form 10-Q Financial Statement

#000089626222000066 Filed on October 27, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3
Revenue $562.1M $558.0M
YoY Change 0.49% 0.81%
Cost Of Revenue $316.2M $322.2M
YoY Change 5.51% 3.83%
Gross Profit $245.9M $239.8M
YoY Change -5.3% -2.81%
Gross Profit Margin 43.75% 42.97%
Selling, General & Admin $193.4M $188.3M
YoY Change 4.64% 5.26%
% of Gross Profit 78.66% 78.55%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $5.230M $5.477M
YoY Change -42.77% -26.85%
% of Gross Profit 2.13% 2.28%
Operating Expenses $198.7M $193.8M
YoY Change 2.41% 3.97%
Operating Profit $47.24M $38.90M
YoY Change -28.07% -31.51%
Interest Expense -$5.314M $4.963M
YoY Change 199.55% 81.79%
% of Operating Profit -11.25% 12.76%
Other Income/Expense, Net $412.0K -$4.111M
YoY Change -16.26% 416.46%
Pretax Income $41.34M $34.82M
YoY Change -11.83% -37.79%
Income Tax $9.790M $9.417M
% Of Pretax Income 23.68% 27.04%
Net Earnings $31.72M $25.64M
YoY Change -6.84% -43.03%
Net Earnings / Revenue 5.64% 4.6%
Basic Earnings Per Share $0.79
Diluted Earnings Per Share $0.97 $0.79
COMMON SHARES
Basic Shares Outstanding 32.49M shares 32.44M shares
Diluted Shares Outstanding 32.62M shares

Balance Sheet

Concept 2022 Q4 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $40.54M $17.96M
YoY Change -5.05% -85.57%
Cash & Equivalents $40.50M $18.00M
Short-Term Investments
Other Short-Term Assets $26.40M $37.84M
YoY Change 3.13% 169.82%
Inventory
Prepaid Expenses $11.63M $17.01M
Receivables $296.8M $302.5M
Other Receivables $0.00 $0.00
Total Short-Term Assets $389.0M $388.8M
YoY Change 9.05% -10.19%
LONG-TERM ASSETS
Property, Plant & Equipment $16.00M $17.25M
YoY Change -13.21% -15.37%
Goodwill $1.287B $1.285B
YoY Change 7.63% 8.2%
Intangibles $101.2M $103.7M
YoY Change -8.98% -12.2%
Long-Term Investments $60.50M $61.50M
YoY Change 13.94% 27.33%
Other Assets $79.80M $81.12M
YoY Change 9.28% 19.11%
Total Long-Term Assets $1.587B $1.593B
YoY Change 5.8% 5.89%
TOTAL ASSETS
Total Short-Term Assets $389.0M $388.8M
Total Long-Term Assets $1.587B $1.593B
Total Assets $1.976B $1.982B
YoY Change 6.42% 2.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $43.74M $45.53M
YoY Change 14.44% 9.31%
Accrued Expenses $137.4M $130.1M
YoY Change -8.91% -15.66%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $15.50M $12.60M
YoY Change 19.23% -4.55%
Total Short-Term Liabilities $355.5M $367.2M
YoY Change -5.01% -19.18%
LONG-TERM LIABILITIES
Long-Term Debt $419.4M $443.4M
YoY Change -2.94% 1.98%
Other Long-Term Liabilities $4.800M $13.87M
YoY Change -3.6% -56.63%
Total Long-Term Liabilities $424.2M $457.3M
YoY Change -2.95% -2.04%
TOTAL LIABILITIES
Total Short-Term Liabilities $355.5M $367.2M
Total Long-Term Liabilities $424.2M $457.3M
Total Liabilities $869.7M $912.5M
YoY Change -1.25% -7.72%
SHAREHOLDERS EQUITY
Retained Earnings $757.7M $726.0M
YoY Change 18.56% 19.99%
Common Stock $755.1M $750.9M
YoY Change 3.7% 4.17%
Preferred Stock
YoY Change
Treasury Stock (at cost) $461.2M $461.2M
YoY Change 5.81% 9.63%
Treasury Stock Shares 5.373M shares 5.373M shares
Shareholders Equity $1.052B $1.016B
YoY Change
Total Liabilities & Shareholders Equity $1.976B $1.982B
YoY Change 6.42% 2.3%

Cashflow Statement

Concept 2022 Q4 2022 Q3
OPERATING ACTIVITIES
Net Income $31.72M $25.64M
YoY Change -6.84% -43.03%
Depreciation, Depletion And Amortization $5.230M $5.477M
YoY Change -42.77% -26.85%
Cash From Operating Activities $40.88M -$13.63M
YoY Change 691.39% -122.07%
INVESTING ACTIVITIES
Capital Expenditures $2.029M -$1.845M
YoY Change -246.29% -22.84%
Acquisitions
YoY Change
Other Investing Activities $163.0K $812.0K
YoY Change -101.59% -100.31%
Cash From Investing Activities -$1.866M -$1.033M
YoY Change -84.01% -99.61%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -16.34M -2.641M
YoY Change -78.48% -101.11%
NET CHANGE
Cash From Operating Activities 40.88M -13.63M
Cash From Investing Activities -1.866M -1.033M
Cash From Financing Activities -16.34M -2.641M
Net Change In Cash 22.67M -17.30M
YoY Change -127.5% -148.66%
FREE CASH FLOW
Cash From Operating Activities $40.88M -$13.63M
Capital Expenditures $2.029M -$1.845M
Free Cash Flow $38.85M -$11.78M
YoY Change 492.92% -118.37%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Registrant Name
EntityRegistrantName
AMEDISYS INC
dei Entity Central Index Key
EntityCentralIndexKey
0000896262
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Costs And Expenses
CostsAndExpenses
1464339000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
203756000 usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Entity Address Address Line1
EntityAddressAddressLine1
3854 American Way
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite A
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
0-24260
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
11-3131700
dei Entity Address City Or Town
EntityAddressCityOrTown
Baton Rouge
dei Entity Address State Or Province
EntityAddressStateOrProvince
LA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
70816
dei City Area Code
CityAreaCode
225
dei Local Phone Number
LocalPhoneNumber
292-2031
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
AMED
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
32491988 shares
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17956000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42694000 usd
CY2022Q3 us-gaap Restricted Cash
RestrictedCash
13504000 usd
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
3075000 usd
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
302470000 usd
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
274961000 usd
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
17011000 usd
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
10356000 usd
CY2022Q3 us-gaap Other Assets Current
OtherAssetsCurrent
37839000 usd
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
25598000 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
388780000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
356684000 usd
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
102407000 usd
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
96937000 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17248000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
18435000 usd
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
105843000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
101257000 usd
CY2022Q3 us-gaap Goodwill
Goodwill
1285455000 usd
CY2021Q4 us-gaap Goodwill
Goodwill
1196090000 usd
CY2022Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
11891000 usd
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
19900000 usd
CY2022Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
103678000 usd
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
111190000 usd
CY2022Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
0 usd
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
289000 usd
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
81123000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
73023000 usd
CY2022Q3 us-gaap Assets
Assets
1982127000 usd
CY2021Q4 us-gaap Assets
Assets
1856968000 usd
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
45527000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
38217000 usd
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
145073000 usd
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
141001000 usd
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
130100000 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
150836000 usd
CY2022Q3 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
12628000 usd
CY2021Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
12995000 usd
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
33872000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
31233000 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
367200000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
374282000 usd
CY2022Q3 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
443431000 usd
CY2021Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
432075000 usd
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
72030000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
69309000 usd
CY2022Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
15983000 usd
CY2021Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
0 usd
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
13873000 usd
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4979000 usd
CY2022Q3 us-gaap Liabilities
Liabilities
912517000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
880645000 usd
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q3 us-gaap Number Of States In Which Entity Operates
NumberOfStatesInWhichEntityOperates
36 state
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q3 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0 usd
CY2021Q4 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0 usd
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37852059 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37674868 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32479475 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32509969 shares
CY2022Q3 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
38000 usd
CY2021Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
38000 usd
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
750914000 usd
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
728118000 usd
CY2022Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
5372584 shares
CY2021Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
5164899 shares
CY2022Q3 us-gaap Treasury Stock Value
TreasuryStockValue
461168000 usd
CY2021Q4 us-gaap Treasury Stock Value
TreasuryStockValue
435868000 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
725955000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
639063000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
1015739000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
931351000 usd
CY2022Q3 us-gaap Minority Interest
MinorityInterest
53871000 usd
CY2021Q4 us-gaap Minority Interest
MinorityInterest
44972000 usd
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1069610000 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
976323000 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1982127000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1856968000 usd
CY2022Q3 us-gaap Health Care Organization Revenue Net Of Patient Service Revenue Provisions
HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
557988000 usd
CY2021Q3 us-gaap Health Care Organization Revenue Net Of Patient Service Revenue Provisions
HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
553485000 usd
us-gaap Health Care Organization Revenue Net Of Patient Service Revenue Provisions
HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
1661135000 usd
us-gaap Health Care Organization Revenue Net Of Patient Service Revenue Provisions
HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
1654795000 usd
CY2022Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
0 usd
CY2021Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-4000 usd
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
0 usd
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
13300000 usd
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
322227000 usd
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
310294000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
943258000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
916188000 usd
CY2022Q3 us-gaap Labor And Related Expense
LaborAndRelatedExpense
125550000 usd
CY2021Q3 us-gaap Labor And Related Expense
LaborAndRelatedExpense
119373000 usd
us-gaap Labor And Related Expense
LaborAndRelatedExpense
376788000 usd
us-gaap Labor And Related Expense
LaborAndRelatedExpense
349533000 usd
CY2022Q3 us-gaap Share Based Compensation
ShareBasedCompensation
3495000 usd
CY2021Q3 us-gaap Share Based Compensation
ShareBasedCompensation
4397000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
15990000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
17860000 usd
CY2022Q3 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
59299000 usd
CY2021Q3 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
55158000 usd
us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
167851000 usd
us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
158995000 usd
CY2022Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
5477000 usd
CY2021Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
7487000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
19705000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
21763000 usd
CY2022Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
3009000 usd
CY2021Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
3009000 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 usd
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
519057000 usd
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
496709000 usd
us-gaap Costs And Expenses
CostsAndExpenses
1526601000 usd
us-gaap Costs And Expenses
CostsAndExpenses
1464339000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
38931000 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
56772000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
134534000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
203756000 usd
CY2022Q3 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
59000 usd
CY2021Q3 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
0 usd
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
108000 usd
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
49000 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
4963000 usd
CY2021Q3 us-gaap Interest Expense
InterestExpense
2730000 usd
us-gaap Interest Expense
InterestExpense
16447000 usd
us-gaap Interest Expense
InterestExpense
6734000 usd
CY2022Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
302000 usd
CY2021Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
1444000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-442000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
3932000 usd
CY2022Q3 us-gaap Gain Loss On Investments
GainLossOnInvestments
0 usd
CY2021Q3 us-gaap Gain Loss On Investments
GainLossOnInvestments
0 usd
us-gaap Gain Loss On Investments
GainLossOnInvestments
0 usd
us-gaap Gain Loss On Investments
GainLossOnInvestments
31092000 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
491000 usd
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
490000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1155000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1253000 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4111000 usd
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-796000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-15626000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
29592000 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
34820000 usd
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
55976000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
118908000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
233348000 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9417000 usd
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
10731000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
32755000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
57192000 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
25403000 usd
CY2021Q3 us-gaap Profit Loss
ProfitLoss
45245000 usd
us-gaap Profit Loss
ProfitLoss
86153000 usd
us-gaap Profit Loss
ProfitLoss
176156000 usd
CY2022Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-239000 usd
CY2021Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
239000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-739000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
1131000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
25642000 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
45006000 usd
us-gaap Net Income Loss
NetIncomeLoss
86892000 usd
us-gaap Net Income Loss
NetIncomeLoss
175025000 usd
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.79
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.38
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.67
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
5.36
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32482000 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32607000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32519000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32658000 shares
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.79
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.37
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.66
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
5.30
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32616000 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32899000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32680000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33021000 shares
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1038995000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
966000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
306000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3495000 usd
CY2022Q3 amed Surrendered Shares
SurrenderedShares
3187000 usd
CY2022Q3 amed Contributions Attributable To Noncontrolling Interest
ContributionsAttributableToNoncontrollingInterest
1148000 usd
CY2022Q3 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
450000 usd
CY2022Q3 us-gaap Noncontrolling Interest Increase From Sale Of Parent Equity Interest
NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
2934000 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
25403000 usd
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1069610000 usd
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
875887000 usd
CY2021Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1061000 usd
CY2021Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1083000 usd
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4397000 usd
CY2021Q3 amed Surrendered Shares
SurrenderedShares
9750000 usd
CY2021Q3 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
10805000 usd
CY2021Q3 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
459000 usd
CY2021Q3 us-gaap Noncontrolling Interest Increase From Business Combination
NoncontrollingInterestIncreaseFromBusinessCombination
42142000 usd
CY2021Q3 us-gaap Profit Loss
ProfitLoss
45245000 usd
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
948801000 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
976323000 usd
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2857000 usd
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1078000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
15990000 usd
amed Surrendered Shares
SurrenderedShares
7949000 usd
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
17351000 usd
amed Contributions Attributable To Noncontrolling Interest
ContributionsAttributableToNoncontrollingInterest
11000000 usd
us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
1425000 usd
us-gaap Noncontrolling Interest Increase From Sale Of Parent Equity Interest
NoncontrollingInterestIncreaseFromSaleOfParentEquityInterest
2934000 usd
us-gaap Profit Loss
ProfitLoss
86153000 usd
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1069610000 usd
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
810741000 usd
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
3022000 usd
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1706000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
17860000 usd
amed Surrendered Shares
SurrenderedShares
16694000 usd
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
84879000 usd
us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
1253000 usd
us-gaap Noncontrolling Interest Increase From Business Combination
NoncontrollingInterestIncreaseFromBusinessCombination
42142000 usd
amed Net Service Revenue Period Of Care Payment Rate Duration
NetServiceRevenuePeriodOfCarePaymentRateDuration
P30D
us-gaap Profit Loss
ProfitLoss
86153000 usd
us-gaap Profit Loss
ProfitLoss
176156000 usd
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
948801000 usd
us-gaap Profit Loss
ProfitLoss
176156000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
19705000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
21763000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
15990000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
17860000 usd
amed Amortizationand Impairmentof Operating Lease Right Of Use Asset
AmortizationandImpairmentofOperatingLeaseRightOfUseAsset
34782000 usd
amed Amortizationand Impairmentof Operating Lease Right Of Use Asset
AmortizationandImpairmentofOperatingLeaseRightOfUseAsset
30181000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-507000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
64000 usd
us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
0 usd
us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
31092000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
19031000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
34729000 usd
amed Net Service Revenue Period Of Care Payment Rate Duration
NetServiceRevenuePeriodOfCarePaymentRateDuration
P30D
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-442000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
3932000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
743000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
669000 usd
us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
3798000 usd
us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
4268000 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
3009000 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
18266000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
17638000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
19929000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6219000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-283000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
938000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5886000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1192000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-26790000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-9363000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
243000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-1785000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-30864000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-27372000 usd
amed Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-2323000 usd
amed Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-2304000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
92400000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
183727000 usd
us-gaap Proceeds From Sale Of Restricted Investments
ProceedsFromSaleOfRestrictedInvestments
89000 usd
us-gaap Proceeds From Sale Of Restricted Investments
ProceedsFromSaleOfRestrictedInvestments
126000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
66000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
140000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4338000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5187000 usd
us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
848000 usd
us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
147000 usd
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
0 usd
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
637000 usd
us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
15000000 usd
us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
0 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
71952000 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
264872000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-92620000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-269940000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1078000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1706000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
2857000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
3022000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
7949000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
16694000 usd
amed Cash Contribution To Noncontrolling Interest
CashContributionToNoncontrollingInterest
2100000 usd
amed Cash Contribution To Noncontrolling Interest
CashContributionToNoncontrollingInterest
0 usd
amed Cash Distribution To Noncontrolling Interest
CashDistributionToNoncontrollingInterest
1425000 usd
us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
3941000 usd
amed Cash Distribution To Noncontrolling Interest
CashDistributionToNoncontrollingInterest
1253000 usd
us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
0 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
290312000 usd
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
484000000 usd
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
500700000 usd
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
465500000 usd
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
551700000 usd
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
10126000 usd
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
5893000 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
2792000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
17351000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
84879000 usd
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
5714000 usd
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
0 usd
amed Funds Received From Provider Relief Fund Advance
FundsReceivedFromProviderReliefFundAdvance
0 usd
amed Funds Received From Provider Relief Fund Advance
FundsReceivedFromProviderReliefFundAdvance
-1465000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-14089000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
131064000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-14309000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
44851000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45769000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
83357000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
31460000 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
128208000 usd
us-gaap Interest Paid Net
InterestPaidNet
9153000 usd
us-gaap Interest Paid Net
InterestPaidNet
3479000 usd
amed Cash Paid For Infinity Zpic Interest
CashPaidForInfinityZPICInterest
11544000 usd
amed Cash Paid For Infinity Zpic Interest
CashPaidForInfinityZPICInterest
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
23582000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
25482000 usd
amed Cash Paid For Operating Lease Liabilities
CashPaidForOperatingLeaseLiabilities
33187000 usd
amed Cash Paid For Operating Lease Liabilities
CashPaidForOperatingLeaseLiabilities
29676000 usd
amed Cash Paid For Finance Lease Liabilities
CashPaidForFinanceLeaseLiabilities
1074000 usd
amed Cash Paid For Finance Lease Liabilities
CashPaidForFinanceLeaseLiabilities
1509000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
36980000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
34881000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
1846000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
814000 usd
amed Lessee Operatinglease Reductionsto Ro Uassetsresultingfromreductionstoleaseobligations
LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations
3387000 usd
amed Lessee Operatinglease Reductionsto Ro Uassetsresultingfromreductionstoleaseobligations
LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations
1183000 usd
amed Lessee Finance Lease Reductions To Right Of Use Assets Resulting From Reductions To Finance Lease Liabilities
LesseeFinanceLeaseReductionsToRightOfUseAssetsResultingFromReductionsToFinanceLeaseLiabilities
564000 usd
amed Lessee Finance Lease Reductions To Right Of Use Assets Resulting From Reductions To Finance Lease Liabilities
LesseeFinanceLeaseReductionsToRightOfUseAssetsResultingFromReductionsToFinanceLeaseLiabilities
0 usd
amed Non Cash Accrued Contingent Consideration
NonCashAccruedContingentConsideration
19195000 usd
amed Non Cash Accrued Contingent Consideration
NonCashAccruedContingentConsideration
0 usd
amed Non Cash Noncontrolling Interest Contribution
NonCashNoncontrollingInterestContribution
8900000 usd
amed Non Cash Noncontrolling Interest Contribution
NonCashNoncontrollingInterestContribution
0 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounting and reporting policies conform with U.S. GAAP. In preparing the unaudited condensed consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</span></div>
CY2022Q3 amed Minimum Percent Ownership For Controlling Interest Percent
MinimumPercentOwnershipForControllingInterestPercent
0.50
CY2022Q3 amed Maximum Percent Ownership For Equity Method Percent
MaximumPercentOwnershipForEquityMethodPercent
0.50
CY2022Q3 us-gaap Equity Method Investment Aggregate Cost
EquityMethodInvestmentAggregateCost
41500000 usd
CY2021Q4 us-gaap Equity Method Investment Aggregate Cost
EquityMethodInvestmentAggregateCost
48100000 usd
CY2022Q3 amed Maximum Percent Ownership For Cost Method Percent
MaximumPercentOwnershipForCostMethodPercent
0.20
CY2022Q1 us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
15000000 usd
CY2022Q3 us-gaap Investment Owned At Cost
InvestmentOwnedAtCost
20000000 usd
CY2021Q4 us-gaap Investment Owned At Cost
InvestmentOwnedAtCost
5000000 usd
CY2022Q3 amed Gain Related To Sale Of Noncontrolling Interest Net Of Tax
GainRelatedToSaleOfNoncontrollingInterestNetOfTax
2900000 usd
amed Historical Collection Rate From Medicare
HistoricalCollectionRateFromMedicare
0.99
CY2022Q3 amed Revenuebypayorclassasapercentageoftotalnetservicerevenue
Revenuebypayorclassasapercentageoftotalnetservicerevenue
1
CY2021Q3 amed Revenuebypayorclassasapercentageoftotalnetservicerevenue
Revenuebypayorclassasapercentageoftotalnetservicerevenue
1
amed Revenuebypayorclassasapercentageoftotalnetservicerevenue
Revenuebypayorclassasapercentageoftotalnetservicerevenue
1
amed Revenuebypayorclassasapercentageoftotalnetservicerevenue
Revenuebypayorclassasapercentageoftotalnetservicerevenue
1
amed Net Service Revenue Period Of Care Payment Rate Duration
NetServiceRevenuePeriodOfCarePaymentRateDuration
P30D
amed Net Service Revenue Episode Payment Rate Duration
NetServiceRevenueEpisodePaymentRateDuration
P60D
amed Net Service Revenue Episode Payment Rate Duration
NetServiceRevenueEpisodePaymentRateDuration
P60D
amed Net Service Revenue Period Of Care Payment Rate Duration
NetServiceRevenuePeriodOfCarePaymentRateDuration
P30D
amed Net Service Revenue Period Of Care Payment Rate Duration
NetServiceRevenuePeriodOfCarePaymentRateDuration
P30D
CY2022Q3 amed Hospice Medicare Revenue Rate Accounted For Routine Care
HospiceMedicareRevenueRateAccountedForRoutineCare
0.97
amed Net Service Revenue Period Of Care Payment Rate Duration
NetServiceRevenuePeriodOfCarePaymentRateDuration
P30D
amed Percentage Of Total Reimbursement Of Outlier Payment
PercentageOfTotalReimbursementOfOutlierPayment
0.10
amed Net Service Revenue Period Of Care Payment Rate Duration
NetServiceRevenuePeriodOfCarePaymentRateDuration
P30D
amed Net Service Revenue Period Of Care Payment Rate Duration
NetServiceRevenuePeriodOfCarePaymentRateDuration
P30D
CY2021Q3 amed Hospice Medicare Revenue Rate Accounted For Routine Care
HospiceMedicareRevenueRateAccountedForRoutineCare
0.97
amed Hospice Medicare Revenue Rate Accounted For Routine Care
HospiceMedicareRevenueRateAccountedForRoutineCare
0.97
amed Hospice Medicare Revenue Rate Accounted For Routine Care
HospiceMedicareRevenueRateAccountedForRoutineCare
0.97
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18000000.0 usd
CY2020Q1 amed Funding Immediately Distributed To Healthcare Providers Based On Their2019 Medicare Fee For Service Reimbursements
FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements
30000000000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42700000 usd
CY2022Q3 us-gaap Restricted Cash
RestrictedCash
13500000 usd
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
3100000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
31500000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45800000 usd
amed Percentage Of Patient Receivables Outstanding
PercentageOfPatientReceivablesOutstanding
0.10
CY2022Q3 amed Accounts Receivable Portion Derived From Medicare
AccountsReceivablePortionDerivedFromMedicare
0.65
CY2021Q4 amed Accounts Receivable Portion Derived From Medicare
AccountsReceivablePortionDerivedFromMedicare
0.68
amed Historical Collection Rate From Medicare
HistoricalCollectionRateFromMedicare
0.99
amed Net Service Revenue Period Of Care Payment Rate Duration
NetServiceRevenuePeriodOfCarePaymentRateDuration
P30D
CY2022Q3 amed Debt Instrument Carrying Amount Excluding Finance Leases
DebtInstrumentCarryingAmountExcludingFinanceLeases
457400000 usd
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32482000 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32607000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32519000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32658000 shares
CY2022Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
38000 shares
CY2021Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
113000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
50000 shares
CY2022Q3 amed Total Leverage Ratio
TotalLeverageRatio
1.8
CY2022Q3 amed Consolidated Interest Coverage Ratio
ConsolidatedInterestCoverageRatio
13.3
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
135000 shares
CY2022Q3 amed Non Vested Stock And Stock Units
NonVestedStockAndStockUnits
96000 shares
CY2021Q3 amed Non Vested Stock And Stock Units
NonVestedStockAndStockUnits
179000 shares
amed Non Vested Stock And Stock Units
NonVestedStockAndStockUnits
111000 shares
amed Non Vested Stock And Stock Units
NonVestedStockAndStockUnits
228000 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32616000 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32899000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32680000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33021000 shares
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
202000 shares
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
141000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
276000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
82000 shares
CY2020Q1 amed Funding For Healthcare Providers Including Hospitals
FundingForHealthcareProvidersIncludingHospitals
175000000000 usd
CY2020Q1 amed Funding Immediately Distributed To Healthcare Providers Based On Their2019 Medicare Fee For Service Reimbursements
FundingImmediatelyDistributedToHealthcareProvidersBasedOnTheir2019MedicareFeeForServiceReimbursements
30000000000 usd
CY2020Q2 amed Funding Received From Cares Act
FundingReceivedFromCARESAct
100000000 usd
amed Cares Act Provider Relief Funds Utilized
CARESActProviderReliefFundsUtilized
46600000 usd
CY2021Q4 amed Cares Act Interest Repaid To Government
CARESActInterestRepaidToGovernment
200000 usd
CY2021Q4 amed Cares Act Provider Relief Fund Amounts Repaid
CARESActProviderReliefFundAmountsRepaid
58300000 usd
amed Cares Act Provider Relief Funds Utilized By Unconsolidated Joint Ventures
CARESActProviderReliefFundsUtilizedByUnconsolidatedJointVentures
1300000 usd
CY2021Q4 amed Cares Act Provider Relief Fund Amounts Repaid By Unconsolidated Joint Ventures
CARESActProviderReliefFundAmountsRepaidByUnconsolidatedJointVentures
600000 usd
CY2021Q4 amed Total Cares Act Provider Relief Funds Received
TotalCARESActProviderReliefFundsReceived
106800000 usd
CY2021Q3 amed Extension Of Temporary Suspension Of Sequestration Revenue Impact
ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact
9000000 usd
amed Extension Of Temporary Suspension Of Sequestration Revenue Impact
ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact
13000000 usd
amed Extension Of Temporary Suspension Of Sequestration Revenue Impact
ExtensionOfTemporarySuspensionOfSequestrationRevenueImpact
27000000 usd
amed Health Insurance Retention Limit
HealthInsuranceRetentionLimit
1300000 usd
amed Workers Compensation Insurance Retention Limit
WorkersCompensationInsuranceRetentionLimit
2000000 usd
amed Professional Liability Insurance Retention Limit
ProfessionalLiabilityInsuranceRetentionLimit
300000 usd
CY2022Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
459800000 usd
CY2021Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
449600000 usd
CY2022Q3 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
3800000 usd
CY2021Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
4500000 usd
CY2022Q3 us-gaap Long Term Debt
LongTermDebt
456000000.0 usd
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
445100000 usd
CY2022Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
12600000 usd
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
13000000.0 usd
CY2022Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
443400000 usd
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
432100000 usd
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
4 segments
CY2022Q3 us-gaap Health Care Organization Revenue Net Of Patient Service Revenue Provisions
HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
558000000.0 usd
CY2022Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
322200000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
188400000 usd
CY2022Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
5500000 usd
CY2022Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
3000000.0 usd
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
519100000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
38900000 usd
CY2021Q3 us-gaap Health Care Organization Revenue Net Of Patient Service Revenue Provisions
HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
553500000 usd
CY2021Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
0 usd
CY2021Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
310300000 usd
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
178900000 usd
CY2021Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
7500000 usd
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
496700000 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
56800000 usd
us-gaap Health Care Organization Revenue Net Of Patient Service Revenue Provisions
HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
1661100000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
943300000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
560600000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
19700000 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
3000000.0 usd
us-gaap Costs And Expenses
CostsAndExpenses
1526600000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
134500000 usd
us-gaap Health Care Organization Revenue Net Of Patient Service Revenue Provisions
HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
1654800000 usd
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
13300000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
916200000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
526400000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
21800000 usd

Files In Submission

Name View Source Status
amed-20220930_def.xml Edgar Link unprocessable
0000896262-22-000066-index-headers.html Edgar Link pending
0000896262-22-000066-index.html Edgar Link pending
0000896262-22-000066.txt Edgar Link pending
0000896262-22-000066-xbrl.zip Edgar Link pending
amed-20220930.htm Edgar Link pending
amed-20220930.xsd Edgar Link pending
amed-20220930_g1.jpg Edgar Link pending
amed-20223009xexhibit101.htm Edgar Link pending
amed-20223009xexx311.htm Edgar Link pending
amed-20223009xexx312.htm Edgar Link pending
amed-20223009xexx321.htm Edgar Link pending
amed-20223009xexx322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
amed-20220930_cal.xml Edgar Link unprocessable
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
amed-20220930_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
amed-20220930_pre.xml Edgar Link unprocessable
amed-20220930_htm.xml Edgar Link completed